quinoxalines has been researched along with mdv 3100 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dong, X; Feng, T; Gao, L; Han, B; Hu, J; Lu, Q; Sun, F; Wang, L; Wang, S; Wang, X; Xiong, X; Zhao, R; Zhou, Q | 1 |
| Cashman, JR; Cheng, J; Gomez-Galeno, J; Lee, DH; Moore, S; Okolotowicz, KJ | 1 |
2 other study(ies) available for quinoxalines and mdv 3100
| Article | Year |
|---|---|
TXNDC9 regulates oxidative stress-induced androgen receptor signaling to promote prostate cancer progression.
Topics: Animals; Benzamides; Cell Proliferation; Disease Progression; Gene Expression Regulation, Neoplastic; Heterografts; Humans; Male; Mice; Nitriles; Oxidative Stress; Peroxiredoxins; Phenylthiohydantoin; Prostate; Prostatic Neoplasms, Castration-Resistant; Protein Stability; Proto-Oncogene Proteins c-mdm2; Quinoxalines; Reactive Oxygen Species; Receptors, Androgen; Signal Transduction; Thioredoxins | 2020 |
A Novel Small Molecule Inhibits Tumor Growth and Synergizes Effects of Enzalutamide on Prostate Cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Aspartate Aminotransferases; Benzamides; Cell Line, Tumor; Drug Synergism; Humans; Male; Mice; Nitriles; Phenylthiohydantoin; Piperazines; Prostatic Neoplasms; Quinoxalines; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2019 |